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BACKGROUND: Src family kinases control multiple cancer cell properties including cell cycle progression, survival, and metastasis. Recent
studies suggest that the Src inhibitor dasatinib blocks these critical cancer cell functions.
METHODS: Because the molecular mechanism of action of dasatinib in breast cancers has not been investigated, we evaluated the
effects of dasatinib as a single agent and in combination with the commonly used chemotherapeutic doxorubicin, on the proliferation,
viability, and invasive capacity of breast cancer cells lines earlier categorised as dasatinib-sensitive (MDA-MB-231) and moderately
resistant (MCF7 and T47D). We also tested the effects of these drugs on the actin cytoskeleton and associated signalling pathways.
RESULTS: The cell lines tested varied widely in sensitivity to growth inhibition (IC50¼0.16–12.3mM), despite comparable Src kinase
inhibition by dasatinib (IC50¼17–37nM). In the most sensitive cell line, MDA-MB-231, dasatinib treatment induced significant G1
accumulation with little apoptosis, disrupted cellular morphology, blocked migration, inhibited invasion through Matrigel (Po0.01),
and blocked the formation of invadopodia (Po0.001). Importantly, combination treatment with doxorubicin resulted in synergistic
growth inhibition in all cell lines and blocked the migration and invasion of the highly metastatic, triple-negative MDA-MB-231 cell line.
CONCLUSION: The observed synergy between dasatinib and doxorubicin warrants the re-evaluation of dasatinib as an effective agent in
multi-drug regimens for the treatment of invasive breast cancers.
British Journal of Cancer (2009) 101, 38–47. doi:10.1038/sj.bjc.6605101 www.bjcancer.com
Published online 9 June 2009
& 2009 Cancer Research UK
Keywords: dasatinib; Src; invasion; invadopodia; breast cancer
                                                     
Src family kinases are critical regulators of normal cellular growth,
migration, adhesion, and survival (Thomas and Brugge, 199 7; Irby
and Yeatman, 2000; Frame, 2002; Playford and Schaller, 2004).
Aberrant expression or activation of Src family kinases causes
perturbation of these activities, leading to transformation and
progression of malignant disease (Irby et al, 1997, 1999; Dehm
and Bonham, 2004; Gallick, 2004). Elevated Src activity has been
shown to increase growth rate (Mao et al, 1997) and metastatic
potential, while inhibiting cell–cell adhesion (Hamaguchi et al,
1993) in human cancers. Elevated Src kinase activity has been
noted in human breast cancers. Although Src activity may be
increased 4- to 20-fold in breast cancer tumours as compared with
normal tissues, this increase is not always accompanied by
corresponding increases in Src protein expression (Rosen et al,
1986; Ottenhoff-Kalff et al, 1992; Verbeek et al, 1996; Summy and
Gallick, 2003). Interaction of Src with numerous breast cancer-
associated growth factors and signalling pathways, such as
prolactin (Acosta et al, 2003), EGFR (Biscardi et al, 2000),
ERK1/2, PI3-kinase (Gaben et al, 2004), and oestrogen receptor
(Migliaccio et al, 2005), supports the notion that Src activity
contributes to the growth and survival of breast cancer cells.
Inhibition of Src kinase activity has been shown to inhibit cell
growth and migration in both in vitro and in vivo systems. Using a
dominant-negative form of Src, Gonzalez et al (2006) demon-
strated that interruption of aberrant Src activity in MCF7 cells
inhibited the spreading, attachment, proliferation, and migration
of these cells in vitro while decreasing their tumorigenicity and
increasing their rate of apoptosis in vivo. A recent study
demonstrated that the Src inhibitor SKI-606 blocks the invasion
of basal-type MDA-MB-231 breast cancer cells in vitro, as well as
the spontaneous metastasis of MDA-MB-231 cells from the
mammary fat pad of nude mice (Jallal et al, 2007).
Dasatinib (BMS-354825, Sprycel) is an orally active Src kinase
inhibitor currently approved for imatinib-resistant/intolerant
BCR-ABLþ leukaemias. Dasatinib is currently under evaluation
in phase II clinical trials for solid tumours. Known chemically as
[N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-
1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5carboxamide], dasa-
tinib inhibits Abl and Src family kinases at low concentrations
(IC50 o1.0nM). At higher concentrations, dasatinib may inhibit
other tyrosine kinases such as p38, Akt, FAK, and the receptor
tyrosine kinases PDGFR, c-kit, and Ephrin (Lombardo et al, 2004).
This drug also has shown antiproliferative effects in lung and
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(Lombardo et al, 2004; Nam et al, 2005; Song et al, 2006; Park
et al, 2008). Recently, Finn et al (2007) demonstrated the selective
efficacy of dasatinib in ‘triple-negative’ breast cancer cells, which
lack oestrogen receptor, progesterone receptor, and HER2 (Boggon
and Eck, 2004). However, the molecular pathways and downstream
effects of dasatinib in breast cancer cells have not been
investigated earlier.
The cytostatic and antimetastatic properties of dasatinib make it
a promising component of multi-drug regimens when paired with
cytotoxic agents such as anthracyclines. In this study, we evaluated
the effects of dasatinib alone, and in combination with doxor-
ubicin, on the proliferation, cell cycle distribution, viability, and
invasive capacity of select breast cancer cell lines. We found that
dasatinib inhibits both cell cycle progression and invasiveness in
sensitive cells. Furthermore, the combination of doxorubicin and
dasatinib synergistically decreased cell metabolism, proliferation,
and viability in the dasatinib insensitive MCF7 cell line, lowering
the IC50 of doxorubicin by more than one log unit. Additionally,
combination treatment of dasatinib-sensitive MDA-MB-231 cells
produced a stronger inhibition of migration and invasion than
with either drug alone. These results indicate that dasatinib
synergizes with the anthracycline doxorubicin to kill a variety of
breast cancer cell lines, and provides a rationale for including
dasatinib as a cytostatic, anti-invasive agent in multi-drug
regimens for primary breast cancers.
MATERIALS AND METHODS
Cell culture
MDA-MB-231, MCF7, and T47D cell lines were obtained from the
ATCC by Drs Gordon Mills and Janet Price (MD Anderson Cancer
Center, Houston, Texas, USA). All cell lines were grown at 371C
and in 5% CO2. MDA-MB-231 and T47D cells were maintained in
DMEM/F12 media (Invitrogen, Carlsbad, CA, USA) supplemented
with 10% fetal calf serum (Hyclone, Logan, UT, USA), 100U/ml
penicillin, and 100mg/ml streptomycin. MCF7 cells were main-
tained in MEM media (Invitrogen) supplemented with 10% fetal
calf serum, 100U/ml penicillin, 100mg/ml streptomycin, 2mM
L-glutamine, 0.1mM non-essential amino acids, 1mM sodium
pyruvate, and MEM vitamin solution.
Antibodies and reagents
Dasatinib was provided by Bristol-Myers Squibb Pharmaceutical
Research Institute (Princeton, NJ, USA) and kept dissolved in
DMSO at  201C. Doxorubicin was purchased from Sigma
(St Louis, MO, USA). Commercially available antibodies used
were: p38 MAPK, CrkL, Akt, phospho-Src (Y416), phospho-Src
(Y527), phospho-p130
CAS (Y410), phospho-FAK (Y576), phospho-
p38 MAPK (T180/Y182), phospho-Abl (Y245), phospho-CrkL
(Y207), phospho-Akt (S473), phospho-Erk1/2 (T202/Y204), and
phospho-Akt-substrate (RXRXXS/T) from Cell Signaling (Danvers,
MA, USA); c-Src, p130
CAS, Abl, Erk1/2, p27
Kip1, and actin from
Santa Cruz Biotechnology (Santa Cruz, CA, USA); cortactin and
phospho-tyrosine (4G10) from Upstate Biotechnology (Billerica,
MA, USA); p21
WAF1 from BD Biosciences (San Jose, CA, USA) and
AlexaFluor488-phalloidin and Cy3-anti-mouse from Invitrogen;
phospho-N-WASP (Y256) and N-WASP from ECM Biosciences
(Versailles, KY, USA).
Viability and proliferation assays
For cell counting and trypan blue exclusion, cells were grown in
the appropriate media plus dasatinib for up to 72h, collected by
scraping, diluted in trypan blue dye, and counted with a Bright-
line hemocytometer (Hausser Scientific, Horsham, PA, USA).
Proliferation was determined using an MTT assay (#M5655, Sigma-
Aldrich). Cells were seeded at a density of 3–5 10
3 cells per well
of 96-well plate with complete medium 24h prior to treatment.
Cells were then treated for 24, 48, and 72h before MTT reagent was
added and absorbance was read at 570nm, per manufacturer’s
instructions.
Cell cycle and cell death assays
Cell cycle distribution was analysed by plating cells at a density of
3–4 10
5 cells per 10cm culture dish with complete medium 24h
prior to treatment. Cells were then treated with dasatinib for 48h,
collected, fixed in 70% ethanol, washed, and stained with a 5%
propidium iodide solution. Samples were detected with a
FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA) and
analysed with FlowJo software (Tree Star Inc., Ashland, OR, USA).
Annexin-V and propidium iodine staining were performed with a
flow cytometric apoptosis detection kit (BD Pharmingen, San Jose,
CA, USA) per the published manual and analysed by FACSCalibur.
BrdU and 7-AAD staining and analyses were performed per the
manufacturer’s published protocols (FITC Flow Kit, BD Bio-
sciences).
Immunoprecipitation and Immunoblotting
Cells were grown in complete media overnight, treated with
dasatinib for 2–48h, washed, collected by scraping, and lysed in
1% NP-40 buffer supplemented with the appropriate proteinase
and phosphatase inhibitors. Protein concentrations were deter-
mined by a Bradford assay and equal amounts of each sample were
either prepared for loading or immunoprecipitated overnight with
the appropriate antibody. Samples were then incubated with
Protein A-Sepharose beads (Sigma), pelleted by centrifugation,
washed and released by boiling in Laemmli sample buffer. Western
blot analysis was performed with whole cell lysates or immuno-
precipitated samples resolved by SDS–PAGE and transferred onto
Immobilon-P Transfer Membranes (Millipore Corp, Billerica, MA,
USA). The membranes were blocked overnight with blocking
buffer (5% milk or 5% BSA, depending on the antibody, with 0.1%
Tween-20). The blots were incubated with primary and then
secondary antibodies for 1h each at room temperature. Immunor-
eactive bands were visualised by enhanced chemiluminescence
(Amersham, Piscataway, NJ, USA). Membranes were then stripped
for 30min at 371C using Stripping buffer (Pierce, Rockford, IL,
USA), reblocked, and probed for actin, GAPDH, or the non-
phosphorylated protein being analysed as loading controls.
Densitometric analysis was performed using the NIH software,
ImageJ (Macintosh platform, Bethesda, MD, USA), to determine
the ratio of phosphorylated protein to total protein. For Src-
pY416:c-Src, IC50 values were calculated based on exponential
regressions of the plotted ratios using Microsoft Excel. For IC50
values of Src inhibition, ratio values of Src-pY416 to total Src were
generated by exponential regression (Microsoft Excel).
Immunofluorescence
Cells were grown and treated on glass chamber slides or glass
coverslips, fixed in 4% paraformaldehyde, permeabilised with 0.1%
Triton X-100, blocked in 1% BSA, and stained with anti-a-tubulin
(Sigma) and Alexa-488 fluorescent phalloidin (Molecular Probes,
Carlsbad, CA, USA). Tubulin staining was detected with a Cy3-
conjugated donkey anti-mouse antibody (Jackson Immuno-
Research, West Grove, PA, USA). Slides were prepared using
ProLong Antifade mounting media (Molecular Probes), and
imaged with a Nikon Eclipse TE2000U microscope and Meta-
Morph imaging software (Molecular Devices, Toronto, Canada).
Invadopodia were analysed by seeding cells on a thin layer of
FITC-labeled gelatin (VWR, West Chester, PA, USA) as described
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and the slides were then processed as described above, stained first
for cortactin and then with Cy3-anti-mouse. Invadopodia were
counted from 10 random fields in each sample (blinded) and
averaged.
Cell migration and invasion assays
Migration was measured by wound healing assay, in which cells
were grown to 80% confluence in 6-well plates, streaked with a
sterile pipette tip, and allowed to recover in dasatinib-treated
media. After 6h, plates were visualised at  10 magnification and
migration determined by measuring wound width (in pixels) using
the MetaMorph imaging software (Molecular Devices, Toronto,
Canada). Invasiveness was determined using Matrigel invasion
chambers with an 8mm-pore membrane (BD Biosciences) seeded
with 2.5 10
4 cells each. Dasatinib-treated media was used in both
the upper and lower chambers, with serum added only to the lower
chamber. Cells were allowed to invade for 24h through the
Matrigel, at which point the inserts were removed and the
membranes scrubbed and fixed in methanol. Invading cells were
then stained and mounted on slides with Prolong Antifade with
DAPI (Molecular Probes). Membranes were then visualised with an
epifluorescent microscope (Nikon, Tokyo, Japan), and quantifica-
tion of invading cells (visualised as DAPI-stained nuclei) was
determined in six random fields per sample.
Statistics
Descriptive statistics including mean values and s.d. were calculated
using Microsoft Excel or Prism software (GraphPad, La Jolla, CA,
USA). Statistical significance was determined by two-sample student
t-tests (P¼0.05). Calculation of GI50 (Dm) values, measures of
sigmoidicity (m), correlation coefficients (r), and combination indices
(CI) of multi-drug treatments were performed using the CalcuSyn
software (Biosoft, Cambridge, UK). Degree of cooperation between
dasatinib and doxorubicin was determined from the combination
index (CI) as follows: CI41 indicates antagonism; CI¼1i n d i c a t e s
additivity; 14CI40.3 indicates synergy; 0.34CI40.1 indicates
strong synergy (Chou, 1976; Chou and Talalay, 1981).
RESULTS
Dasatinib inhibits proliferation and metabolism of
sensitive MDA-MB-231 cells
Because the molecular mechanism of action of dasatinib against
breast cancer cells has not been studied earlier, we examined the
effects of dasatinib on three commonly studied breast cancer cell
lines, MDA-MB-231, MCF7, and T47D, which were previously
characterised as highly sensitive (MDA-MB-231) and moderately
resistant (MCF7, T47D) to dasatinib (Finn et al, 2007). To compare
dasatinib-induced inhibition of metabolic activity, cells were
treated with increasing doses of dasatinib for 48h and metabolic
activity was quantified by MTT assay. The IC50 for metabolic
inhibition was calculated from these data (Figure 1A). MDA-MB-
231 cells demonstrated the strongest inhibition with a calculated
IC50 of 0.16mM. MCF7 and T47D cells were less responsive, with
IC50 doses of 12.3 and 0.45mM, respectively. Cell counts taken over
72h of treatment with 100nM dasatinib demonstrated an increase
in the doubling time of MDA-MB-231 cells, whereas MCF-7 cell
proliferation was less affected (Figure 1B). Dasatinib treatment of
MDA-MB-231 cells achieved significant inhibition (Po0.01) of cell
proliferation at 0.05mM, whereas MCF7 did not exhibit significant
inhibition with doses lower than 1.0mM.I C 50 doses for dasatinib
calculated from cell counts after 72h of dasatinib treatment
demonstrated a three-fold difference between MDA-MB-231 and
MCF7 (0.33mM and 0.99mM, respectively). BrdU uptake by
replicating MDA-MB-231 cells was also significantly reduced from
35% (DMSO control) to 12%. IC50 values calculated from the uptake
of BrdU demonstrated the same trend, in which MDA-MB-231 are
the most sensitive and MCF7 the most resistant. To test for cell death
due to dasatinib treatment, cells were treated with dasatinib and
percent viability after 48h of treatment was determined by trypan
blue exclusion. No decrease in cell viability was observed in MDA-
MB-231 cells, although a slight decrease in viability was noted in
MCF7 cells (Figure 1B). The absence of dasatinib-induced apoptosis
in MDA-MB-231 cells was confirmed by flow cytometric analysis of
Annexin-V and PI staining (data not shown). Furthermore, no
increase in PARP cleavage was detected in lysates of MDA-MB-231
or T47D cells after 48h of treatment (Figure 2C).
The degree of Src inhibition does not correlate with
proliferative inhibition by dasatinib
Given the wide variation in dasatinib sensitivity across breast cancer
cell lines, we examined whether Src inhibition was a useful
biomarker for dasatinib response. The IC50 values for Src inhibition
were calculated from the dose-dependent dephosphorylation of
tyrosine 416, which is an activating phosphorylation site within Src
(Figure 1C). We observed that, despite their wide variability in
metabolic response, all three cell lines exhibited comparable
inhibition Src activity. Within 2h, Src phosphorylation was
attenuated by 475% in all cell lines following treatment with
100nM dasatinib, which is an achievable dose in clinical trials
(Copland et al, 2006). Interestingly, the IC50 values for Src inhibition,
which ranged between 16.7–37.0nM, were much lower than the
doses required for 50% inhibition of metabolic activity. As an
additional measure of Src activation, we also examined the
phosphorylation state of Src on tyrosine 527 (Y527), which is an
inhibitory phosphorylation site. Dephosphorylation of Y527 was also
observed with dasatinib treatment (Figure 1C), although at much
higher concentrations (10-fold) than required for 50% inhibition of
the activating (Y416) site phosphorylation. This may indicate a non-
specific inhibition of the activity of the C-terminal Src kinase, Csk, at
high doses of dasatinib (Roskoski, 2005; Lieser et al, 2006).
We also examined basal levels of phospho-Src (Y416) across a
panel of breast cancer cell lines to determine whether basal Src
activity was a predictor of dasatinib sensitivity. Basal phospho-Src
(Y416) levels were not dramatically different between these three
lines (Supplementary Figure 1). Interestingly, we found that the
weakly invasive MDA-MB-468 cell line had very high levels of basal
Y416 phosphorylation. However, despite the strong basal phos-
phorylation in these cells, phospho-Y416 was still completely
inhibited by 100nM dasatinib treatment (Supplementary Figure 1)
and the cells were calculated to have an IC50 for metabolic activity
of more than 10mM. This indicates that neither basal Src activity
nor loss of Y416 phosphorylation following dasatinib treatment are
adequate predictors of dasatinib sensitivity. We also considered
whether other kinases known to be inhibited by dasatinib were
relevant markers of dasatinib effectiveness in these breast cancer
cell lines. In this regard, dasatinib has been reported to block the
activities of c-kit, PDGFR and the ephrin receptor (EphA2) at
similar doses required for Src inhibition in vitro (Lombardo et al,
2004; Chen et al, 2006; Schittenhelm et al, 2006; Wang et al, 2007).
However, c-kit and PDGFR were not expressed in the dasatinib-
sensitive MDA-MB-231 cell line (Supplementary Figure 1) (Hines
et al, 1995; Meric et al, 2002). On the other hand, although we
observed that the ephrin receptor was highly expressed in the
sensitive MDA-MB-231 cells, dasatinib did not alter its tyrosine
phosphorylation (data not shown) (Zelinski et al, 2001). These
data indicate that c-kit, PDGFR, and Ephrin receptor, known
targets of dasatinib, were not effective markers for dasatinib
sensitivity in these breast cancer cell lines. This does not exclude
the possibility that unknown targets of dasatinib are being
inhibited when using high doses of the drug.
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cells
Owing to the inability of dasatinib to induce cell death, we
reasoned that the observed inhibition of proliferation could result
from a block in cell cycle progression. Dasatinib-induced cell cycle
arrest has not been investigated in solid tumours. Therefore, cell
cycle distribution was measured after 48-h dasatinib treatment
(Figure 1D). MDA-MB-231 cells demonstrated a significant
increase in the proportion of cells in G1 phase after 1mM dasatinib
treatment (64 vs 41%; Po0.001). MCF7 and T47D cells, however,
showed no significant change in cell cycle distribution (Figure 1D).
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Figure 1 Inhibition of cell growth and G1 progression in dasatinib-sensitive breast cancer cells. (A) Cells were grown in 96-well plates with complete
medium, then treated with dasatinib for 48h before analysis by MTT assay. Results are shown as a percent of DMSO-treated samples and represent the
mean of four independent assays with 4–5 replicates each. Error bars are standard error of the mean (s.e.m.). Asterisks denote significance in comparison to
MDA-231 sample within each treatment dose. (B) Cells were plated in 6-well dishes with complete medium and treated with dasatinib for 48h. Samples
were collected at indicated time points and counted with a hemocytometer. Viability was determined by trypan blue exclusion. BrdU positivity was analysed
by flow cytometry. (C) Cells were treated with DMSO or dasatinib for 2h and whole cell lysates probed for phospho-Src (Y416 or Y527), stripped, and
reprobed for c-Src. Response for each dose was calculated as the ratio of phospho-Src to total-Src. IC50 was calculated by best-fit regression of data points.
(D) Cells were treated for 48h with DMSO, 0.1 or 1.0mM dasatinib, fixed, and stained with propidium iodide, and analysed by flow cytometry for cell cycle
distribution. (E) Whole lysates of cells treated with 100nM dasatinib for 2h (72h for p27 blot, as indicated) were probed for phospho-Akt substrate, actin,
and p27. Results are representative of at least three independent experiments. *Indicates Po0.05; **indicates Po0.01.
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ming that dasatinib did not induce cell death. To verify G1 arrest in
MDA-MB-231 cells, we investigated the status of cell cycle regula-
tory proteins Cdk2 and p27
Kip1 after dasatinib treatment (Sherr
and Roberts, 1999). Cdk2 phosphorylation on an activating site
was sharply decreased after 100nM of dasatinib in MDA-MB-231
cells, but not in MCF7 or T47D cells. In addition, p27 accumu-
lation, an indicator of cell cycle arrest, was observed only in the
MDA-MB-231 cells after 72h of dasatinib treatment (Figure 1E).
Combination treatment of dasatinib and doxorubicin
synergistically inhibits metabolism and growth
Dasatinib is likely to be used in combination with traditional
chemotherapeutics, so we examined whether combination treat-
ment with a cytotoxic agent such as doxorubicin could heighten
the sensitivity to either drug. Dose–response curves were
generated to investigate the synergistic effects of combination
therapy with dasatinib and doxorubicin on cell proliferation using
an MTT assay (Figure 3A). In MDA-MB-231 cells, dasatinib
treatment alone inhibited proliferation at an IC50 of 160nM,
whereas doxorubicin alone blocked proliferation at an IC50 of
140nM (Figure 3B). On the other hand, treatment with a 1:1 drug
combination (simultaneous administration) inhibited proliferation
at a much lower IC50 of 35nM for each drug. Calculation of the
combination index (CI), in which values below 1 indicate synergy,
demonstrates moderate synergism of the two drugs (CI¼0.47).
Interestingly, the synergistic effects of the two drugs were
considerably stronger in MCF7 and T47D cells, where dasatinib
alone had very weak effects on proliferation. The CI values
calculated for 50% inhibition of these cells were 0.05 and 0.04,
respectively, indicating very strong synergy. In the most dasatinib-
resistant cell line, MCF7 (IC50¼12mM), combination treatment of
the drugs in a 1:1 ratio inhibited cell growth by 50% at 7.6nM of
each drug. Similarly in T47D cells, 50% inhibition of cell growth
was achieved at 6.6nM of each drug. These values represent a
dramatic decrease in the dosage of either dasatinib or doxorubicin
required for comparable levels of growth inhibition with either
drug alone. Specifically, in MCF7 cells the dose of doxorubicin
needed for 50% growth inhibition can be decreased by 95% (from
150 to 7.6nM) when given in combination with an equal dose
of dasatinib. Similarly, in T47D cells the IC50 for doxorubicin can
be decreased by 98% (293–6.6nM). These changes represent
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Figure 2 Synergistic growth inhibition by dasatinib–doxorubicin combinations. (A) Cells were grown in 96-well plates with complete medium and
treated with dasatinib alone, doxorubicin alone, or both drugs in combination (1:1 ratio) for 48h before analysis by MTT assay. Metabolic rates are shown as
percentages of the control (DMSO)-treated sample. (B)I C 50 values for each drug (Dm) and combination indexes (CIs) were calculated by logarithmic
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shown as the mean of five replicates and are representative of at least two independent experiments. (C) Cells were treated 48h with either drug alone or
in combination (1:1 ratio). BrdU was added for last 1h of culture before cells were collected and assessed for viability (by trypan blue exclusion) and cell
cycle distribution. 7-AAD was used to stain total DNA. BrdU positivity represents cells actively replicating in the last hour of culture. **Indicates Po0.01.
Dasatinib blocks breast cancer growth and invasion
CS Pichot et al
42
British Journal of Cancer (2009) 101(1), 38–47 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
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chemotherapeutic agent, doxorubicin, in blocking proliferation in
these cells.
We then examined whether the synergistic effect of dasatinib
and doxorubicin on growth inhibition was the result of altered
rates of cell cycle progression or apoptosis. In MDA-MB-231 cells,
viability was not greatly affected by any drug combination.
However, addition of dasatinib to the doxorubicin treatment did
reduce the population of BrdU-positive cells from 5.8 to 3.9%
(Figure 3C). Analysis of cell cycle distribution by flow cytometry
confirmed that there was a significant decrease in the percentage of
cells in S phase (Figure 2A). We also observed that the
doxorubicin-mediated G2/M arrest was predominant over dasati-
nib-induced G1 arrest in cells treated with the drug combination,
such that 82.6% of live cells were in G2/M phase after 48h of
treatment (Figure 2A). This was not significantly different than
G2/M accumulation in cells treated with doxorubicin alone (82.1%
in G2/M). Consistent with the dominant G2/M arrest in the
doxorubicin-treated cells, similar levels of accumulation of
p21
WAF1 were observed after treatment with either doxorubicin
alone or dasatinib plus doxorubicin (Figure 2C). These data
indicate that co-treatment with dasatinib did not significantly alter
the effects of doxorubicin on cell cycle progression or cell viability
in MDA-MD-231 cells.
On the other hand, in MCF7 cells the combination treatment did
enhance cell killing, reducing viability from 52.0% with doxo-
rubicin treatment alone to 36.4% with the combination treatment.
This may contribute to the strong synergy between dasatinib and
doxorubicin seen in the MCF7 cells. Importantly, as with dasatinib
treatment alone, there was no increase in PARP cleavage after
combination treatment (Figure 2C), suggesting that the increase in
cell death was the result of a non-apoptotic mechanism. To
determine whether the synergy between dasatinib and doxorubicin
resulted from differential effects on Src activation, the level of
Src (Y416) phosphorylation in MDA-MB-231 and MCF7 cells
was examined. However, combination treatment did not
induce additive inhibition of Src in either cell type (Figure 2B).
Taken together, these results suggest that the synergy between
doxorubicin and dasatinib in MDA-MB-231 and MCF7 cells results
from inhibition of distinct pathways, neither of which can be
accounted for by altered sensitivity to Src inhibition.
Dasatinib-sensitive cells undergo cytoskeletal contraction
The mesenchymal-like MDA-MB-231 cells normally grow as
flattened, spindle-shaped cells, characterised by many filopodia-
like processes. Upon dasatinib treatment, however, the cells
displayed a very different morphology that was characterised by
a round, contracted appearance. As seen in Figure 4A, the
actin and tubulin cytoskeletal structure of the cells was disrupted,
creating a dense and compact cell body in which the intricate
actin branching structures appeared to have collapsed and
filamentous tubulin is compacted. On the other hand, only minor
changes in morphology were observed in the MCF7 and T47D
(Figure 4B) cells treated with a dasatinib concentration
(100nM) that clearly inhibited Src activation (Figure 1C). This is
consistent with the reduced effectiveness of dasatinib on the
growth of these cells.
To determine whether inhibition of cytoskeletal regulatory
proteins might predict dasatinib-sensitivity, cells were treated with
dasatinib and protein lysates probed for phosphorylation of the
cytoskeletal regulatory proteins focal adhesion kinase (FAK),
p130
CAS, and CrkL, each of which are substrates of Src family
kinases (Gonzalez et al, 2006). In MDA-MB-231 and T47D cells, we
observed that dasatinib treatment strongly inhibited FAK phos-
phorylation at the activating site Y576. MCF7 cells exhibited low
basal phospho-FAK (Y576), which was also comparably affected
(Figure 4C). Active FAK phosphorylates N-WASP, a Cdc42 effector
protein that promotes branched actin polymerisation, at Y256.
Dasatinib treatment also inhibited N-WASP phosphorylation at
Y256 in MDA-MB-231, MCF7, and T47D cells (Figure 4D).
Although more basal N-WASP phosphorylation was present in
the T47D cells (compared with MDA-MB-231 cells, data not
shown), residual phosphorylation after dasatinib treatment was
comparable. In addition, dasatinib treatment induced a dose-
dependent reduction in the phosphorylation of p130
CAS, which was
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Figure 3 Effects of combination treatment on cell cycle progression and phospho-Src. (A) Cells were treated 48h with either drug alone or in
combination (1:1 ratio), then collected and assessed for cell cycle distribution by 7-AAD staining. Flow cytometry was used to analyse staining of fixed cells.
(B) Protein lysates of MDA-MB-231, MCF7, and T47D cells treated for 2h were immunoblotted as indicated for pSrc-Y416, stripped and reprobed for total
Src. (C) Cells were treated for 48h with DMSO, 100nM dasatinib, 100nM doxorubicin, or 100nM of each drug. Whole lysates were immunoblotted for
PARP, p21
WAF1, and GAPDH.
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CrkL was comparable in all three lines, dephosphorylation of CrkL
(Y207) was only evident in MDA-MB-231 and T47D cells, with no
significant change in MCF7 lysates. Given the high basal CrkL
phosphorylation in all three cell lines and the selective depho-
sphorylation of CrkL only in dasatinib-sensitive cells, decreased
CrkL tyrosine phosphorylation appeared to most accurately reflect
dasatinib sensitivity. Thus, CrkL dephosphorylation on Y207 may
serve as an effective biomarker for dasatinib response in future
studies.
Because Src can positively regulate Akt through PI3K,
we investigated whether phospho-Akt may also be a marker
for dasatinib sensitivity. Consistent with the characteristics
of mesenchymal-like tumours, MDA-MB-231 cells exhibited a
high level of basal Akt activity. Dasatinib treatment strongly
inhibited the phosphorylation of Akt at serine 473 in MDA-
MB-231 cells, indicative of decreased Akt activity. MCF7
cells, which retain a more epithelial phenotype, had lower
levels of basal Akt (S473) phosphorylation that were not
affected by dasatinib treatment. T47D cells also did not
demonstrate any loss in pAkt with dasatinib treatment. Because
we did not observe any increase in apoptosis with
dasatinib treatment, it is unlikely that dasatinib-inhibition of Akt
is affecting cell survival pathways. Previous studies have suggested
a role for Akt in the regulation of cell cycle progression via
phosphorylation of Cdk2 and p27
Kip1 (Shin et al, 2002; Grille
et al, 2003; Maddika et al, 2008), which were inhibited by
dasatinib only in the MDA-MB-231 cells (Figure 1E). Thus, the
dephosphorylation of Akt and its downstream substrates in MDA-
MB-231 cells following dasatinib treatment suggests that phospho-
rylation of these proteins may serve as indirect markers for
dasatinib efficacy.
Migration and invasion are inhibited by dasatinib
treatment
Based on the observed morphology changes in MDA-MB-231 cells
following dasatinib treatment, we investigated the functional
effects of dasatinib on cell migration and invasion. MCF7 and
T47D cells were not tested because they are resistant to migration
along the edge of a wound, are not invasive, and responded poorly
to dasatinib. To measure effects on cell migration we used streak
assays, where the ability of cells to repopulate a wounded area in a
monolayer can be measured. We observed that untreated MDA-
MB-231 cells were highly motile and repopulated the denuded area
within 24h. However, following dasatinib treatment, migration
into the wounded area was greatly abrogated with a clear dose-
dependent association (Figure 5A, Po0.05). To measure cell
invasion, we used a Boyden chamber assay with Matrigel-coated
filters. In these assays invasion through the Matrigel by MDA-MB-
231 cells was decreased by 88% with 50nM dasatinib treatment
(Figure 5B; Po0.01). To confirm that these effects were due to
cytoskeletal defects and not a result of inhibited cell proliferation,
we studied the formation of invadopodia in individual invading
cells. Invadopodia are actin-rich, finger-like projections that
protrude into the extracellular matrix, secreting proteinases to
degrade the matrix and allow for invasion of a cell through the
barrier (Weaver, 2006). By plating MDA-MB-231 cells on a
fluorescently-labeled gelatin substrate, we are able to visualise
discrete points of matrix degradation and cytoskeletal extensions,
which are identified as active invadopodia (Clark et al, 2007).
Dasatinib treatment reduced the average number of invadopodia
per cell from 5.4 to 0.4, indicating a near complete blockage of
cytoskeletal remodelling activity and invasive capacity (Figure 5C;
Po0.05).
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Figure 4 Dasatinib treatment disrupts cytoskeletal organisation and cellular invasion. (A, B) MDA-MB-231 (A), MCF7, and T47D (B) cells were grown
on glass chamber slides and treated with dasatinib for 48h before staining with antitubulin antibody and FITC-phalloidin. (C) MDA-MB-231, MCF7, and
T47D cells were treated with increasing doses of dasatinib (DMSO, 10, 25, or 100nM) for 2h. Whole cell lysates were immunoblotted for phospho -
FAK(Y576), -p130 (Y410) and -CrkL (Y207) . Membranes were then stripped and reprobed for total p130, FAK, or CrkL, respectively. (D) Cells were
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sWe then determined whether doxorubicin and dasatinib
synergized to block the migratory and invasive capacity of
MDA-MB-231 cells. Cells were treated with 100nM dasatinib,
alone or in combination with an equimolar dose of doxorubicin.
In these assays, doxorubicin treatment alone only weakly
affected the migration of MDA-MB-231 cells. However, in
combination with dasatinib, the antimigratory effect was
significantly stronger (Figure 5D; Po0.05). Because the
wound assay is performed at a short time point (6h),
effects on proliferation cannot account for this difference.
In the Matrigel invasion assay, doxorubicin treatment alone
reduced invasion of MDA-MB-231 cells to a level near that
achieved with an equal dose of dasatinib. Importantly, in
combination treatment, the level of invasion was further
reduced (Figure 5D; Po0.05). These data indicate that combina-
tion treatment with dasatinib and doxorubicin elicited greater
effects on migration and invasion than either drug alone, and
further support a strategy where breast cancers may be more
effectively treated by combining traditional chemotherapeutics
with dasatinib.
DISCUSSION
Src family kinases play critical roles in the progression and
survival of human cancers. Thus we tested whether dasatinib, an
effective Bcr-Abl and Src inhibitor, blocked breast cancer cell
proliferation. For these studies, we evaluated the sensitivity of
three commonly used breast cancer cell lines, MDA-MB-231,
MCF7, and T47D, to dasatinib treatment and investigated the
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sresulting molecular effects. Because cellular response to dasatinib
did not correlate with inhibition of Src kinase activity, we studied
the differential signaling pathways that may mediate dasatinib
sensitivity. Phosphorylation of Src on tyrosine 416, an activating
autophosphorylation site, was consistently inhibited in all cell
lines. Although some loss of phosphorylation at the inhibitory
phosphorylation site tyrosine 527 (Boggon and Eck, 2004) was
observed with high doses of dasatinib (100nM), this was also
consistent across the cell lines tested and did not correlate with
changes in proliferation. Other potential dasatinib targets, such as
PDGFR and c-kit, were not present in these cell lines. Ephrin
receptor was present but not inhibited by dasatinib. Dasatinib also
targets Abl at low concentrations, and the presence of active Abl in
MDA-MB-231 has been previously suggested. However, we were
unable to detect basal phosphorylation of Abl in any of the breast
cancer cell lines we tested (data not shown).
Given the relatively uniform inhibition of Src, we sought to
identify other potential markers that may predict sensitivity to
dasatinib. Previous studies have examined gene expression arrays
to identify potential markers for dasatinib sensitivity and found
that caveolin and moesin mRNAs are downregulated in dasatinib-
sensitive cells after treatment (Finn et al, 2007; Huang et al, 2007).
However, we did not detect any change in the expression of either
protein after 48h of dasatinib treatment in the dasatinib-sensitive
MDA-MB-231 cells (data not shown), indicating that at the protein
level these gene products are unlikely to serve as useful markers.
On the other hand, we observed that phosphorylation of the Src
family kinase substrate CrkL may serve as an effective biomarker
of dasatinib responsiveness. CrkL is an adaptor protein associated
with adhesive properties of cells, and is phosphorylated on Y207 by
Src family kinases. Dasatanib reduced phospho-CrkL (Y207) levels
by 76% in the sensitive MDA-MB-231 cells, while phospho-CrkL
(Y207) decreased by only 17 and 34% in the relatively insensitive
MCF7 and T47D cells, respectively. Based on these data,
phosphorylation of CrkL on Y207 may serve as a biomarker for
dasatinib response in breast cancer cells.
Dasatinib also strongly inhibited Akt phosphorylation at S473 in
the MDA-MB-231 cells, presumably through downregulation of the
PI3K pathway resulting from decreased Src activity (Lu et al,
2003). Although dasatinib can directly inhibit Akt kinase activity
(Lombardo et al, 2004), we observed significant loss of Akt
phosphorylation at 100nM, a dose far below the reported IC50 for
Akt of greater than 50mM. Because only the dasatinib-sensitive
MDA-MB-231 cells showed a reduction in Akt phosphorylation
following dasatinib treatment, decreases in the phosphorylation of
Akt or its downstream substrates may also serve as predictive
markers for dasatinib response.
An important observation of these studies is that dasatinib
treatment induced severe morphological and functional changes in
the sensitive MDA-MB-231 cells. These observations were con-
sistent with the observed reduction in the phosphorylation of
cytoskeletal regulators such as CrkL. Disruption of cytoskeletal
architecture upon treatment resulted in more compact, rounded
cells that lacked the extensively branched actin structures normally
seen in MDA-MB-231 cells. Consequently, migration and invasion
were also dramatically impaired. Dasatinib-treated cells were
unable to re-infiltrate the denuded area in scratch assays. In vitro
invasion of MDA-MB-231 cells was also inhibited by 490%, and
invadopodia formation was almost completely blocked. These
results indicate that the antimetastatic properties of dasatinib may
be mediated by impaired actin polymerisation and cytoskeletal
control. Many factors affect invasiveness, and it cannot be
excluded that the secretion of matrix-degrading enzymes such as
MMP-9 may also be impaired in dasatinib-treated cells, contri-
buting to the loss of invasion. It is likely however, that the severity
of the cytoskeletal defect in MDA-MB-231 and loss of invadopodia
formation, are sufficient to cause the decrease in invasion seen
with dasatinib treatment.
Vigneron et al (2005) demonstrated earlier that aberrant Src
signaling impaired the p21
WAF1-mediated senescence induced by the
anthracycline doxorubicin. Because of these findings, we investigated
whether Src inhibition can strengthen the effects of doxorubicin.
Importantly, we observed that dasatinib sensitises cells to the growth
arrest and cell killing induced by doxorubicin. In vitro experiments
with MCF7 and T47D cells, which are refractory to inhibition by
dasatinib alone, demonstrated that doxorubicin doses could be
reduced 20- to 44-fold in each cell line when combined with an
equivalent dose of dasatinib to maintain the same metabolic
inhibition observed with doxorubicin alone. These levels are below
the maximal plasma concentrations of dasatinib achieved in Phase I
clinical trials, and are therefore clinically relevant (Copland et al,
2006). Furthermore, combination treatment of MDA-MB-231 cells
demonstrated an additive inhibition of migration and invasion,
suggesting that adding dasatinib to a doxorubicin therapy may
further reduce the risk of metastasis. It is important to note that our
studies were performed using simultaneous administration of
dasatinib and doxorubicin in equimolar doses. Modification of the
dosing schedule or drug ratio may further improve the cooperative
actions between these two compounds. Nevertheless, these results
provide strong support for the idea of using dasatinib as an effective
addition to multi-drug regimens with traditional chemotherapeutics
and warrant future investigation.
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